MediciNova, Inc.''s MN-166 Program Recognized as One of Windhover Information Inc.'s Top 10 Neuroscience Projects to Watch  
10/20/2010 11:45:55 AM

SAN DIEGO, Oct. 19, 2010 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number:4875), announced today that its novel macrophage migration inhibitory factor (MIF inhibitor) MN-166 program has been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."